253 related articles for article (PubMed ID: 17353380)
41. Low incidence of restrictive valvulopathy in patients with Parkinson's disease on moderate dose of pergolide.
Růzicka E; Línková H; Penicka M; Ulmanová O; Nováková L; Roth J
J Neurol; 2007 Nov; 254(11):1575-8. PubMed ID: 17712588
[TBL] [Abstract][Full Text] [Related]
42. Heart valvular disease in patients with Parkinson's disease treated with high-dose pergolide.
Van Camp G; Flamez A; Cosyns B; Goldstein J; Perdaens C; Schoors D
Neurology; 2003 Sep; 61(6):859-61. PubMed ID: 14504342
[TBL] [Abstract][Full Text] [Related]
43. Heart valve disease associated with treatment with ergot-derived dopamine agonists: a clinical and echocardiographic study of patients with Parkinson's disease.
Rasmussen VG; Poulsen SH; Dupont E; Østergaard K; Safikhany G; Egeblad H
J Intern Med; 2008 Jan; 263(1):90-8. PubMed ID: 18036161
[TBL] [Abstract][Full Text] [Related]
44. Nocturnal activity with nighttime pergolide in Parkinson disease: a controlled study using actigraphy.
Comella CL; Morrissey M; Janko K
Neurology; 2005 Apr; 64(8):1450-1. PubMed ID: 15851743
[TBL] [Abstract][Full Text] [Related]
45. Switching from pergolide to pramipexole in patients with Parkinson's disease.
Hanna PA; Ratkos L; Ondo WG; Jankovic J
J Neural Transm (Vienna); 2001; 108(1):63-70. PubMed ID: 11261747
[TBL] [Abstract][Full Text] [Related]
46. An exploratory retrospective evaluation of ropinirole-associated psychotic symptoms in an outpatient population treated for restless legs syndrome or Parkinson's disease.
Stoner SC; Dahmen MM; Makos M; Lea JW; Carver LJ; Rasu RS
Ann Pharmacother; 2009 Sep; 43(9):1426-32. PubMed ID: 19690226
[TBL] [Abstract][Full Text] [Related]
47. [Multiple latency test in a patient with episodes of sleep induced by pergolide].
Jiménez-Jiménez FJ; Velasco I; de Toledo M; Sayed Y; Zurdo J; Ortí-Pareja M
Rev Neurol; 2002 Jun 16-30; 34(12):1140-1. PubMed ID: 12134281
[TBL] [Abstract][Full Text] [Related]
48. Rounded atelectasis and respiratory compromise secondary to pergolide use.
Bloom CI; Wilson GE
Respirology; 2009 Aug; 14(6):906-7. PubMed ID: 19659834
[TBL] [Abstract][Full Text] [Related]
49. The frequency of cardiac valvular regurgitation in Parkinson's disease.
Yamashiro K; Komine-Kobayashi M; Hatano T; Urabe T; Mochizuki H; Hattori N; Iwama Y; Daida H; Sakai M; Nakayama T; Mizuno Y
Mov Disord; 2008 May; 23(7):935-941. PubMed ID: 18398916
[TBL] [Abstract][Full Text] [Related]
50. Pergolide in Parkinson's disease: time for a change?
Grosset KA; Grosset DG
Lancet; 2004 Jun; 363(9424):1907-8. PubMed ID: 15183636
[No Abstract] [Full Text] [Related]
51. High risk factors for valvular heart disease from dopamine agonists in patients with Parkinson's disease.
Oeda T; Masaki M; Yamamoto K; Mizuta E; Kitagawa N; Isono T; Taniguchi S; Doi K; Yaku H; Yutani C; Kawamura T; Kuno S; Sawada H
J Neural Transm (Vienna); 2009 Feb; 116(2):171-8. PubMed ID: 19082526
[TBL] [Abstract][Full Text] [Related]
52. Dopamine agonists and valvular heart disease.
Linkova H; Ruzicka E; Penicka M
N Engl J Med; 2007 Apr; 356(16):1676; author reply 1678-80. PubMed ID: 17447279
[No Abstract] [Full Text] [Related]
53. Treatment of Parkinson's disease with ropinirole after pergolide-induced retroperitoneal fibrosis.
Lund BC; Neiman RF; Perry PJ
Pharmacotherapy; 1999 Dec; 19(12):1437-8. PubMed ID: 10600093
[TBL] [Abstract][Full Text] [Related]
54. Dopamine agonists, Dopplers and doubt: cabergoline-associated cardiac valvulopathy.
Pullan PT
Intern Med J; 2009 Apr; 39(4):213-5. PubMed ID: 19402858
[No Abstract] [Full Text] [Related]
55. Cardiac valvulopathy associated with pergolide use.
Zadikoff C; Rochon P; Lang A
Can J Neurol Sci; 2006 Feb; 33(1):27-33. PubMed ID: 16583718
[TBL] [Abstract][Full Text] [Related]
56. Echocardiography for the detection of valvulopathy associated with the use of ergot-derived dopamine agonists in patients with Parkinson's disease.
Nakaoka S; Ishizaki T; Urushihara H; Satoh T; Ikeda S; Morikawa K; Nakayama T
Intern Med; 2011; 50(7):687-94. PubMed ID: 21467699
[TBL] [Abstract][Full Text] [Related]
57. Dopamine agonists and valvular heart disease.
Cheung D; Heaney A
Curr Opin Endocrinol Diabetes Obes; 2009 Aug; 16(4):316-20. PubMed ID: 19506475
[TBL] [Abstract][Full Text] [Related]
58. Dopamine and cognitive functioning in de novo subjects with Parkinson's disease: effects of pramipexole and pergolide on working memory.
Costa A; Peppe A; Dell'Agnello G; Caltagirone C; Carlesimo GA
Neuropsychologia; 2009 Apr; 47(5):1374-81. PubMed ID: 19428401
[TBL] [Abstract][Full Text] [Related]
59. Mitral valve surgery for functional mitral regurgitation: should moderate-or-more tricuspid regurgitation be treated? a propensity score analysis.
Calafiore AM; Gallina S; Iacò AL; Contini M; Bivona A; Gagliardi M; Bosco P; Di Mauro M
Ann Thorac Surg; 2009 Mar; 87(3):698-703. PubMed ID: 19231373
[TBL] [Abstract][Full Text] [Related]
60. Valvular heart disease in pergolide-treated Parkinson's disease.
Scozzafava J; Takahashi J; Johnston W; Puttagunta L; Martin WR
Can J Neurol Sci; 2006 Feb; 33(1):111-3. PubMed ID: 16583734
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
